Free Trial
→ Trump wipes out trillions overnight… (From Porter & Company) (Ad)
NYSE:OGEN

Oragenics 5/15/2024 Earnings Report

Oragenics logo
$0.12 -0.01 (-9.37%)
Closing price 04:00 PM Eastern
Extended Trading
$0.12 0.00 (-0.83%)
As of 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
ProfileEarnings History

Oragenics EPS Results

Actual EPS
-$0.70
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Oragenics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Oragenics Announcement Details

Quarter
Date
5/15/2024
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Oragenics Earnings Headlines

Oragenics, Inc. Announces One-for-Thirty Reverse Stock Split
May 29 at 5:40 AM | finance.yahoo.com
Oragenics Hosts Neurotrauma Medicine Webinar Presentation
May 20, 2025 | tipranks.com
A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
May 30, 2025 | Porter & Company (Ad)
Oragenics gains Australia’s nod for concussion therapy trial
May 15, 2025 | uk.investing.com
Oragenics, Inc. to Host Webinar on ONP-002 and Addressing Unmet Needs in Concussion Treatment
May 14, 2025 | nasdaq.com
Oragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in Australia
May 13, 2025 | globenewswire.com
See More Oragenics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Oragenics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oragenics and other key companies, straight to your email.

About Oragenics

Oragenics (NYSE:OGEN), a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.

View Oragenics Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles